Clinical Practice Session
B Cell-Directed Therapies for Glomerular Diseases
October 25, 2026 | 09:30 AM - 11:30 AM
Location: Four Seasons Ballroom 4, Convention Center
Session Description
Antibody-mediated glomerular diseases are an important cause of kidney disease, particularly in young adults. Over the past decade, novel treatments have evolved to target pathogenic antibody production, offering new ways to achieve disease control and, in some cases, long-term drug-free remission. This session reviews the fundamentals of B-cell dysregulation that drive antibody-mediated glomerular diseases and therapeutic approaches that either modulate B-cell activity or deplete specific B-cell populations. B-cell gene editing is currently being developed to treat several diseases. The session reviews the applicability of this approach to antibody-mediated glomerular diseases.
Learning Objective(s)
- Describe the role of B cells in glomerular diseases
- Describe the role of B cell-depleting therapies in glomerular diseases
- Describe the role of B cell-modulating therapies in glomerular diseases
Learning Pathway(s)
- Glomerular Diseases
- Pediatric Nephrology
Moderators
Presentations
- B-Cell Dysregulation in Glomerular Diseases
09:30 AM - 10:00 AM
- Depleting Approaches: What Have We Learned, and Is This the Answer?
10:00 AM - 10:30 AM
- B-Cell Modulation with B Cell-Activating Factor (BAFF) and/or a Proliferation-Inducing Ligand (APRIL) Inhibitors: When Should We Use Them?
10:30 AM - 11:00 AM
- B-Cell Gene Editing for Autoimmune Kidney Diseases: The Next Frontier?
11:00 AM - 11:30 AM